Indian Journal of Medical and Paediatric Oncology

LinksSchließen

Referenz

Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K. et al.
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: A phase 1 dose-escalation study.

Lancet Oncol 2017;
18: 1512-22

Bibliographische Angaben herunterladen

Aufrufen in: